Difference between revisions of "Rhabdomyosarcoma"

Rhabdomyosarcoma (view source)

No change in size , 13:53, 17 March 2011

→‎IHC: fix sp.

48,466

edits

@@ Line 116: / Line 116: @@
 |}
-A paper bu Wachtel at al.<ref>{{cite journal |author=Wachtel M, Runge T, Leuschner I, ''et al.'' |title=Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry |journal=J. Clin. Oncol. |volume=24 |issue=5 |pages=816–22 |year=2006 |month=February |pmid=16391296 |doi=10.1200/JCO.2005.03.4934 |url=}}</ref> proposes the use of:
+A paper by Wachtel at al.<ref>{{cite journal |author=Wachtel M, Runge T, Leuschner I, ''et al.'' |title=Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry |journal=J. Clin. Oncol. |volume=24 |issue=5 |pages=816–22 |year=2006 |month=February |pmid=16391296 |doi=10.1200/JCO.2005.03.4934 |url=}}</ref> proposes the use of:
 * ''AP2beta'' and ''P-cadherin'' +ve in translocation positive alveolar RMS, and
 * ''EGFR'' and ''fibrillin-2'' +ve in embryonal RMS and translocation negative alveolar RMS.